WallStreetZenWallStreetZen

NASDAQ: BIAF
Bioaffinity Technologies Inc Stock

$2.40+0.02 (+0.84%)
Updated Feb 6, 2023
BIAF Price
$2.40
Fair Value Price
N/A
Market Cap
$20.09M
52 Week Low
$1.31
52 Week High
$15.55
P/E
N/A
P/B
1.59x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.12
Operating Cash Flow
N/A
Beta
1.47
Next Earnings
Mar 1, 2023
Ex-Dividend
N/A
Next Dividend
N/A

BIAF Overview

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.

Zen Score

Industry Average (30)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BIAF scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

BIAF is good value based on its book value relative to its share price (1.59x), compared to the US Diagnostics & Research industry average (4.46x)
P/B vs Industry Valuation
BIAF's short-term assets ($14.05M) exceed its short-term liabilities ($1.46M)
Short-term Liabilities Financials
BIAF's short-term assets ($14.05M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
There are 30 more BIAF due diligence checks available for Premium users.

Be the first to know about important BIAF news, forecast changes, insider trades & much more!

BIAF News

Valuation

BIAF fair value

Fair Value of BIAF stock based on Discounted Cash Flow (DCF)
Price
$2.40
Fair Value
$6.75
Undervalued by
64.44%

BIAF price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
1.59x
Industry
4.46x
BIAF is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

BIAF's financial health

Profit margin

Revenue
$1.2k
Net Income
-$4.9M
Profit Margin
-427,779%

Assets to liabilities

Assets
$14.1M
Liabilities
$1.5M
Debt to equity
0.12
BIAF's short-term assets ($14.05M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BIAF's short-term assets ($14.05M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BIAF's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$1.8M
Investing
$0.0
Financing
$15.0M

BIAF vs Diagnostic & Research Stocks

TickerMarket Cap1d %P/EP/B
BIAF$20.09M+0.84%N/A1.59x
PRPO$20.56M-0.99%-1.73x1.13x
SLNO$18.93M-10.42%-0.70x1.25x
CDIO$17.87M+59.32%-2.11x1.84x
TRIB$22.78M+1.87%N/A3.43x

Bioaffinity Technologies Stock FAQ

What is Bioaffinity Technologies's quote symbol?

NASDAQ: BIAF) Bioaffinity Technologies trades on the NASDAQ under the ticker symbol BIAF. Bioaffinity Technologies stock quotes can also be displayed as NASDAQ: BIAF.

If you're new to stock investing, here's how to buy Bioaffinity Technologies stock.

What is the 52 week high and low for Bioaffinity Technologies (NASDAQ: BIAF)?

(NASDAQ: BIAF) Bioaffinity Technologies's 52-week high was $15.55, and its 52-week low was $1.31. It is currently -84.57% from its 52-week high and 83.21% from its 52-week low.

How much is Bioaffinity Technologies's stock price per share?

(NASDAQ: BIAF) Bioaffinity Technologies stock price per share is $2.40 today (as of Feb 6, 2023).

What is Bioaffinity Technologies's Market Cap?

(NASDAQ: BIAF) Bioaffinity Technologies's market cap is $20.09M, as of Feb 7, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Bioaffinity Technologies's market cap is calculated by multiplying BIAF's current stock price of $2.40 by BIAF's total outstanding shares of 8,369,750.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.